{"ABLI.ST": {"short_name": "Abliva AB", "long_name": "Abliva AB (publ)", "summary": "Abliva AB (publ) engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Karolinska Institutet, Covance, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was founded in 2000 and is headquartered in Lund, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014General", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Lund"}, "L7R.F": {"short_name": "LIPIDOR AB", "long_name": "Lipidor AB (publ)", "summary": "Lipidor AB (publ), a pharmaceutical development company, develops drugs for the treatment of skin diseases. The company develops AKP-01, which is in Phase III for the treatment of psoriasis; and preclinical stage products, such as AKP-02 for psoriasis, AKP-03 for bacterial skin infections, and AKP-07 for atopic dermatitis. It offers active pharmaceutical ingredients used in products for various therapeutic applications, such as anti-psoriasic, antimicrobial, anti-inflammatory, antifungal, local anesthetics, non-steroidal anti-inflammatory, anti-acne, wound healing, anti-eczema, and anti-migraine. The company also develops a range of spray products for animal skin care in dogs, cats, and horses; and consumer health care products for applications, including antibacterial, antiseptic, moisturizing emollient, disinfectant, acne treatment, and wart treatment. Lipidor AB (publ) has a collaboration agreement with Cannassure Therapeutics Ltd. for the development of topical medicinal cannabis products for the treatment of skin inflammations and psoriatic lesions. The company was founded in 2009 and is based in Stockholm, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014General", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Stockholm"}, "LIPI.ST": {"short_name": "Lipidor AB", "long_name": "Lipidor AB (publ)", "summary": "Lipidor AB (publ), a pharmaceutical development company, develops drugs for the treatment of skin diseases. The company develops AKP-01, which is in Phase III for the treatment of psoriasis; and preclinical stage products, such as AKP-02 for psoriasis, AKP-03 for bacterial skin infections, and AKP-07 for atopic dermatitis. It offers active pharmaceutical ingredients used in products for various therapeutic applications, such as anti-psoriasic, antimicrobial, anti-inflammatory, antifungal, local anesthetics, non-steroidal anti-inflammatory, anti-acne, wound healing, anti-eczema, and anti-migraine. The company also develops a range of spray products for animal skin care in dogs, cats, and horses; and consumer health care products for applications, including antibacterial, antiseptic, moisturizing emollient, disinfectant, acne treatment, and wart treatment. Lipidor AB (publ) has a collaboration agreement with Cannassure Therapeutics Ltd. for the development of topical medicinal cannabis products for the treatment of skin inflammations and psoriatic lesions. The company was founded in 2009 and is based in Stockholm, Sweden.", "currency": "SEK", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014General", "exchange": "STO", "market": "se_market", "country": "Sweden", "city": "Stockholm"}, "NEVPF": {"short_name": "ABLIVA AB", "long_name": "Abliva AB (publ)", "summary": "Abliva AB (publ) engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Karolinska Institutet, Covance, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was founded in 2000 and is headquartered in Lund, Sweden.", "currency": "USD", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014General", "exchange": "PNK", "market": "us_market", "country": "Sweden", "city": "Lund"}, "NTP.F": {"short_name": "ABLIVA AB AK", "long_name": "Abliva AB (publ)", "summary": "Abliva AB (publ) engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Karolinska Institutet, Covance, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was founded in 2000 and is headquartered in Lund, Sweden.", "currency": "EUR", "sector": "Healthcare", "industry": "Drug Manufacturers\u2014General", "exchange": "FRA", "market": "dr_market", "country": "Sweden", "city": "Lund"}}